Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Meiji Seika Pharma Pins High Hopes on Schizophrenia Drug Sycrest
Meiji Seika Pharma is gunning for a bigger slice of shares in the Japanese CNS market by boosting its profile in the schizophrenia sector with Sycrest (asenapine) it launched in Japan on May 26, President Daikichiro Kobayashi said. “The drug…
To read the full story
Related Article
- Meiji Plans Japan-Bound Generic Projection in India to Seek Cost Competitiveness
June 1, 2016
- 180 Billion Yen Sales in FY2017 Is “Quite Reachable”: Meiji Seika Pharma President
May 22, 2015
- Meiji Holdings Aims at Sales of 180 Billion Yen and 30% Overseas Sales Ratio in Pharma Business by FY2017
May 19, 2015
BUSINESS
- SSP Looks to Broaden Switch OTC Portfolio under New President
April 13, 2026
- Otsuka Targets Around 2030 US Launch for Transcend’s PTSD Candidate
April 13, 2026
- Nippon Shinyaku, xFOREST Ink RNA-Targeting Small Molecule Research Pact
April 13, 2026
- OTC-Like Drug Reform Seen Adding 190 Billion Yen to Japan OTC Market by 2040: Fuji Keizai
April 13, 2026
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…